has function has role vaccinated in route immunizes against disease immunizes recipient multiple myeloma Homo sapiens subcutaneous route therapeutic vaccine function vaccine in clinical trial role myeloma cancer vaccine dendritic cell/​myeloma fusion vaccine VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6323 Hayleigh Kahn Jie Zheng NCT: https://clinicaltrials.gov/study/NCT02728102 cancer vaccine 6323 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C158480 A cancer vaccine onsisting of autologous dendritic cells (DCs) fused with patient-derived plasma cell (multiple) myeloma cells with potential immunostimulatory and antineoplastic activities. Autologous DC/multiple myeloma fusions stimulate both helper and cytotoxic T-lymphocyte (CTL) responses through the presentation of internalized and newly synthesized tumor associated antigens (TAAs). This may promote cellular and humoral antitumor immune responses in patients with plasma cell myeloma. This vaccine uses Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy. The dendritic cell myeloma vaccine may improve response in patients with multiple myeloma after autologous Hematopoietic Cell Transplant (HCT). therapeutic cancer vaccine whole cell cancer vaccine